- Home
- FORR vs DSGN Comparison
FORR vs DSGN Comparison
Compare FORR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- DSGN
- Stock Information
- Founded
- FORR 1983
- DSGN 2017
- Country
- FORR United States
- DSGN United States
- Employees
- FORR N/A
- DSGN N/A
- Industry
- FORR Diversified Commercial Services
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- DSGN Health Care
- Exchange
- FORR Nasdaq
- DSGN Nasdaq
- Market Cap
- FORR 193.5M
- DSGN 208.9M
- IPO Year
- FORR 1996
- DSGN 2021
- Fundamental
- Price
- FORR $9.58
- DSGN $5.33
- Analyst Decision
- FORR
- DSGN
- Analyst Count
- FORR 0
- DSGN 0
- Target Price
- FORR N/A
- DSGN N/A
- AVG Volume (30 Days)
- FORR 99.6K
- DSGN 116.6K
- Earning Date
- FORR 07-31-2025
- DSGN 08-07-2025
- Dividend Yield
- FORR N/A
- DSGN N/A
- EPS Growth
- FORR N/A
- DSGN N/A
- EPS
- FORR N/A
- DSGN N/A
- Revenue
- FORR $412,103,000.00
- DSGN N/A
- Revenue This Year
- FORR N/A
- DSGN N/A
- Revenue Next Year
- FORR $2.04
- DSGN N/A
- P/E Ratio
- FORR N/A
- DSGN N/A
- Revenue Growth
- FORR N/A
- DSGN N/A
- 52 Week Low
- FORR $8.50
- DSGN $2.60
- 52 Week High
- FORR $19.74
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FORR 42.94
- DSGN 68.46
- Support Level
- FORR $9.68
- DSGN $3.95
- Resistance Level
- FORR $10.45
- DSGN $5.48
- Average True Range (ATR)
- FORR 0.56
- DSGN 0.35
- MACD
- FORR -0.07
- DSGN 0.14
- Stochastic Oscillator
- FORR 10.70
- DSGN 90.23
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.